Jump to content

SkQ

From Wikipedia, the free encyclopedia

SkQ is a class of mitochondria-targeted antioxidants, developed by Professor Vladimir Skulachev and his team. In a broad sense, SkQ is a lipophilic cation, linked via saturated hydrocarbon chain to an antioxidant. Due to its lipophilic properties, SkQ can effectively penetrate through various cell membranes. The positive charge provides directed transport of the whole molecule including antioxidant moiety into the negatively charged mitochondrial matrix. Substances of this type, various drugs that are based on them, as well as methods of their use are patented in Russia and other countries such as United States, China, Japan, and in Europe.[1][2][3][4] Sometimes the term SkQ is used in a narrow sense for the denomination of a cationic derivative of the plant antioxidant plastoquinone.

History

[edit]

In 1969, triphenylphosphonium (TPP, charged triphenylphosphine) was proposed for use for the first time.[5] This compound with a low molecular weight consists of a positively charged phosphorus atom and surrounded by three hydrophobic phenyls that are accumulating in mitochondria. In 1970, the use of the TPP for targeting the delivery of compounds to the mitochondrial matrix was proposed. In 1974, the TPP, as well as its derivatives and other penetrating ions, were named "Skulachev's Ions" by the famous American biochemist David E. Green.[6]

In 1999, the first work on the directed delivery of the antioxidant alpha-tocopherol linked by a hydrocarbon chain to TPP to the mitochondria was published. The compound was named TPPB or MitoVitE.[7] Several years later MitoQ, a better version of a mitochondria-targeted compound was synthesized. Its antioxidant part is represented by ubiquinone, which is linked with a 10-carbon aliphatic chain to TPP.[8]

In the early 2000s, a group of researchers led by prof V. P. Skulachev in Moscow State University began the development of SkQ — the mitochondrial-targeted antioxidant, similar to MitoQ, but with the ubiquinone replaced with plastoquinone (more active analog of ubiquinone derived from plant chloroplasts).[9] Since 2005, several modified SkQ compounds were synthesized and tested in vitro,[10][11] the efficiency and the antioxidant effects of the tested compounds were higher than previous analogs by hundreds of times. All of these compounds have abbreviated names derived from the names of Skulachev (Sk), letters for quinone (Q) and denote the modification (alpha and/or numeric symbol, for example, R1 for a derivative of rhodamine and plastoquinone). The largest amount of data was obtained for SkQ1 and SkQR1.[12][13]

Later SkQ properties were tested in vitro on fibroblasts and in vivo in different organisms: mice, drosophilids, yeast, and many others.[14] It was found that SkQ is able to protect cells from death from oxidative stress and is effective as a treatment of age-related diseases in animals.[15][16]

Since 2008, the development of pharmaceuticals based on SkQ has been started. In 2012, The Ministry of Health of the Russian Federation approved the use of the eye drops "Visomitin" based on SkQ1 for the treatment of dry eye syndrome and the early stage of cataract.[17] Testing of the efficacy of SkQ-drugs against other diseases, both in Russia and in the United States is currently in progress.[18][19]

In 2016, phase 1 of a clinical trial of an oral drug containing SkQ1 was conducted in Russia.[20] In 2017, it was found that SkQ has a strong antibacterial effect and is able to inhibit the activity of multidrug-resistant enzymes in bacteria[21][22] Since 2019 the Skulachev project is developing mitochondrial antioxidants in several areas: synthesis and testing of new SkQ compounds, testing the effects on a variety of model systems and in different diseases.[23]

Classification

[edit]

SkQ compound consists of three parts: antioxidant, C-aliphatic linker and lipophilic cation.

Compounds of SkQ

A list of some of SkQ and substances with similar structure:

SkQ1 lat. 10-(6'-Plastoquinonyl)decyltriphenylphosphonium
SkQR1 lat. 10-(6'-Plastoquinonyl)decylrhodamine-19
SkQ2 lat. 10-(6'-plastoquinonyl)decylcarnitine
SkQ2M lat. 10-(6'-plastoquinonyl)decylmethylcarnitine
SkQ3 lat. 10-(6′-methylplastoquinonyl) decyltriphenylphosphonium
SkQ4 lat. 10-(6'-plastoquinonyl)decyltributylammonium
SkQ5 lat. 5-(6'-plastoquinonyl)amyltriphenylphosphonium
SkQBerb lat. 13-[9-(6-plastoquinonyl) nonyloxycarbonyl-methyl] berberine
SkQPalm lat. 13-[9-(6-plastoquinonyl) nonyloxycarbonyl-methyl] palmatine
C12TPP lat. dodecyltriphenylphosphonium
MitoQ lat. 10-(6-ubiquinoyl)decyltriphenyl-phosphonium

By type of cation

[edit]

Lipophilic cation determines the efficiency of penetration through the membranes into the mitochondrial matrix. The best properties are shown by SkQ-compounds with triphenylphosphonium ion (TPP): MitoQ, SkQ1, and others. Similar penetration efficiency was shown for compounds with rhodamine 19, such as SkQR1. Rhodamine has fluorescence properties, so its derivatives are used in the visualization of mitochondria.[24] The SkQ derivatives with acetylcarnitine (SkQ2M) tributyl ammonium (SkQ4) as lipophilic cations have weak penetrating properties.[25]

The cations with the well-known medical properties — berberine and palmatine were also tested. SkQBerb and SkQPalm – SkQ derivatives, do not differ much in properties from SkQ1 and SkQR1.[26]

The length of the linker

[edit]

In SkQ compounds, a decamethylenic linker (an aliphatic chain of 10 carbon atoms) is used. Reduction of the length of the chain leads to a deterioration in the penetrating ability of ions. The compound with such pentamethylenic linker is demonstrated on SkQ5.[27] Molecular dynamics in the membrane calculated with a computer have shown that the length of the linker of 10 is optimal for the manifestation of antioxidant properties of SkQ1. The quinone residue is located right next to the C9 or C13 atoms of the fatty acids of the membrane that has to be protected from oxidative damage.[28]

The type of antioxidant

[edit]

Compounds without antioxidant part are used to control the effect of SkQ compound. For example, C12-TPP and C12R1 penetrate the mitochondria but do not inhibit the oxidation. Interestingly, these compounds partially demonstrate the positive effects of SkQ. This happens due to the phenomenon of soft depolarization (mild uncoupling) of the mitochondrial membrane. Compounds with tocopherol and ubiquinone for historical reasons are called MitoVitE and MitoQ, although formally they can be attributed to the class of SkQ-compounds. MitoQ is traditionally used for comparison with the SkQ compound.[citation needed]

The highest antioxidant activity was shown for the compounds with thymoquinone (SkQT1 and SkQTК1). Thymoquinone is a derivative of plastoquinone, but with one methyl substituent in the aromatic ring. Next in the sequence of antioxidant activity connection is plastoquinone (SkQ1 and SkQR1), with two methyl substituents. SkQ3 is a less active compound, with three methyl substituents. SkQB without methyl substituents exhibits the weakest antioxidant properties.

In general, SkQ-like compounds can be arrange by its antioxidant activity as follows: SkQB < MitoQ < DMMQ ≈ SkQ3 < SkQ1 < SkQT.[29]

Mechanism of action

[edit]

The positive effect of SkQ is associated with its following properties:[citation needed]

  • penetration into the mitochondria — the main source of reactive oxygen species (ROS) of the cells
  • inhibition of ROS at the site of their formation in two different ways:
  • direct neutralization of ROS due to the oxidation of plastoquinone,
  • reduction of mitochondrial membrane potential

Penetration into the mitochondria

[edit]

Due to its lipophilic properties, SkQ-substances can penetrate the lipid bilayer. The transportation is caused by the electrical potential due to the presence of a positive charge in SkQ. Mitochondria are the only intracellular organelles with a negative charge. Therefore, SkQ effectively penetrates and accumulates there.[citation needed]

The accumulation coefficient can be estimated using the Nernst equation. To do this, we must take into account that the potential of the plasma membrane of the cell is about 60 mV (the cytoplasm has a negative charge), and the potential of the mitochondrial membrane is about 180 mV (the matrix has a negative charge). As a result, the electric gradient SkQ between the extracellular medium and the mitochondrial matrix is 104.

It should also be taken into account that SkQ has a high coefficient of distribution between lipid and water, about 104. Taking this into account, the total concentration gradient of SkQ inside the inner layer of the inner mitochondria membrane can be up to 108.[30]

Direct inhibition of ROS

[edit]

Oxidation of organic substances by ROS is a chain process. Several types of active free radicals — peroxide (RO2*), alkoxyl (RO*), alkyl (R*), and ROS (superoxide anion, singlet oxygen), participate in these chain reactions.

One of the main targets of ROS — cardiolipin, polyunsaturated phospholipid of the inner membrane of mitochondria, which is especially sensitive to peroxidation. After a radical attack on the C11 atom of linoleic acid, cardiolipin forms peroxyl radical, which is stabilized at positions C9 and C13 due to its neighboring double bonds.

The location of the SkQ1 in the mitochondrial membrane is that the plastoquinone residue is exactly near of C9 or C13 of cardiolipin (depending on the SkQ conformation). Thus, it can quickly and effectively quench the peroxyl radical of cardiolipin.[31]

Another important property of SkQ is its recyclability. After ROS neutralization the SkQ antioxidant moiety is converted to its oxidized form (plastoquinone or semi-quinone). Then it can be quickly restored by the complex III of the respiratory chain. Thus, due to the functioning of the respiratory chain, SkQ exists mainly in a restored, active form.

Uncoupling properties

[edit]

In some cases (for example, in experiments on the lifespan of Drosophila or plant models) compound C12-TPP (without the plastoquinone residue) can successfully substitute for SkQ1.[32]

This phenomenon is explained by the fact that any hydrophobic compound with a delocalized positive charge is able to transfer anions of fatty acids from one side of the membrane to another, thus lowering the transmembrane potential.[33] This phenomenon is called uncoupling of respiration and ATP synthesis on the mitochondrial membrane. In the cell, this function is normally performed by uncoupling proteins (or UCPs, including thermogenin from brown fat adipocytes) and ATP/ADP antiporter.

Weak depolarization of the membrane leads to a multiple reductions in the amount of ROS produced by mitochondria.[34]

Pro-oxidant effect

[edit]

At high concentrations (micromolar and more) SkQ-compounds exhibit pro-oxidant properties stimulating ROS production.

The advantage of SkQ1 is that the difference in concentrations between pro- and antioxidant activity is about 1000 fold. Experiments on mitochondria have shown that SkQ1 begins to exhibit antioxidant properties already at concentrations of 1 nM, and pro-oxidant properties at concentrations of about 1 μM. For comparison, this "concentration window" of MitoQ is only about 2-5 fold. The manifestation of antioxidant activity of MitoQ begins only with concentrations of 0.3 μM while it begins to demonstrate pro-oxidant effect at 0.6-1.0 μM.[35]

Anti-inflammatory effect

[edit]

In several experimental models (including experiments on laboratory animals) SkQ1 and SkQR1 showed a pronounced anti-inflammatory effect.[36]

Suppression of multiple drug resistance

[edit]

SkQ1 and C12-TPP are substrates of ABC-transporters. The main function of these enzymes is the protection of cells from xenobiotics. Lipophilic cations compete with other substrates of these carriers and thus weaken the protection of cells from external influences.[37]

Use

[edit]

Medicine

[edit]

SkQ is able to delay the development of several traits of aging and increase the life span in a variety of animals. Depending on the type of SkQ molecule, the substance may reduce early mortality, increase life expectancy and extend the maximum age of experimental animals.[38] Also in various experiments, SkQ has slowed down the development of several age-dependent pathologies and signs of aging.[39][40]

It was shown that SkQ accelerates wound healing,[41] as well as treats age-related diseases such as osteoporosis, cataracts, retinopathy, and others.[42]

At the end of 2008, preparations for the official approval of SkQ-based pharmaceuticals in Russia has started. The efficiency of eye drops against "dry eye syndrome" was also confirmed in the following double-blind placebo-controlled studies: (a) international multicenter study in Russia and Ukraine,[43] phase II study in the United States.[44] A clinical study on patients with age-related cataracts was also successfully conducted. In Russia in 2019 clinical studies are in progress for two improved versions of SkQ1-based eye drops – Visomitin Forte (phase II study on patients with age-related macular degeneration)[45] and Visomitin Ultra (Phase I clinical study).[46]

In 2018-2021, both attempts at Phase III clinical trials in the United States failed to show any statistically significant results among 452 (VISTA-1/NCT03764735)[47] and 610 (VSTA-2/NCT04206020)[48] participants respectively.

Cosmetology

[edit]

SkQ1 is included in the composition of cosmetic products such as Mitovitan Active, Mitovitan, and Exomitin.[49][50]

Veterinary

[edit]

The drug "Visomitin" on the basis of SkQ1 used in veterinary practice for the treatment of ophthalmologic diseases in pets. In particular, the effectiveness is shown for the treatment of retinopathy in dogs, cats, and horses.[51]

Else

[edit]

Experiments have shown an unexpected effect of SkQ on plants. The substance stimulated differentiation (in the treatment of callus) and seed germination (patent US 8,557,733), increased the yield of different crops (Ph.D. thesis of A.I. Uskov).[52]

See also

[edit]

References

[edit]
  1. ^ "Patent Claims". Scientific American. 1 (20): 324–326. 1859-11-12. doi:10.1038/scientificamerican11121859-324. ISSN 0036-8733.
  2. ^ US 9724313, Skulachev, Maxim V., "Pharmaceutical composition for use in medical and veterinary ophthalmology", published 2019-02-26, assigned to Mitotech SA 
  3. ^ US 9328130, Skulachev, Vladimir Petrovich, "Method of treating organism by biologically active compounds specifically delivered into mitochondria, pharmaceutical composition required for the use of the method and a compound applicable for this purpose", published 2016-05-03, assigned to Mitotech SA 
  4. ^ "ЕВРАЗИЙСКАЯ ПАТЕНТНАЯ ОРГАНИЗАЦИЯ (ЕАПО)". www.eapo.org. Retrieved 2019-09-18.
  5. ^ Liberman, E. A.; Topaly, V. P.; Tsofina, L. M.; Jasaitis, A. A.; Skulachev, V. P. (1969-06-14). "Mechanism of coupling of oxidative phosphorylation and the membrane potential of mitochondria". Nature. 222 (5198): 1076–1078. Bibcode:1969Natur.222.1076L. doi:10.1038/2221076a0. ISSN 0028-0836. PMID 5787094. S2CID 4223514.
  6. ^ Green, David E. (1974-04-30). "The electromechanical model for energy coupling in mitochondria". Biochimica et Biophysica Acta (BBA) - Reviews on Bioenergetics. 346 (1): 27–78. doi:10.1016/0304-4173(74)90011-1. ISSN 0304-4173. PMID 4151654.
  7. ^ Smith, R. A.; Porteous, C. M.; Coulter, C. V.; Murphy, M. P. (August 1999). "Selective targeting of an antioxidant to mitochondria". European Journal of Biochemistry. 263 (3): 709–716. doi:10.1046/j.1432-1327.1999.00543.x. ISSN 0014-2956. PMID 10469134.
  8. ^ Kelso, G. F.; Porteous, C. M.; Coulter, C. V.; Hughes, G.; Porteous, W. K.; Ledgerwood, E. C.; Smith, R. A.; Murphy, M. P. (2001-02-16). "Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties". The Journal of Biological Chemistry. 276 (7): 4588–4596. doi:10.1074/jbc.M009093200. ISSN 0021-9258. PMID 11092892.
  9. ^ Kruk, Jerzy; Jemioła-Rzemińska, Małgorzata; Strzałka, Kazimierz (1997-05-30). "Plastoquinol and α-tocopherol quinol are more active than ubiquinol and α-tocopherol in inhibition of lipid peroxidation". Chemistry and Physics of Lipids. 87 (1): 73–80. doi:10.1016/S0009-3084(97)00027-3. ISSN 0009-3084.
  10. ^ Antonenko, Y. N.; Roginsky, V. A.; Pashkovskaya, A. A.; Rokitskaya, T. I.; Kotova, E. A.; Zaspa, A. A.; Chernyak, B. V.; Skulachev, V. P. (April 2008). "Protective effects of mitochondria-targeted antioxidant SkQ in aqueous and lipid membrane environments". The Journal of Membrane Biology. 222 (3): 141–149. doi:10.1007/s00232-008-9108-6. ISSN 0022-2631. PMID 18493812. S2CID 1808377.
  11. ^ Roginsky, Vitaly A.; Tashlitsky, Vadim N.; Skulachev, Vladimir P. (2009-05-12). "Chain-breaking antioxidant activity of reduced forms of mitochondria-targeted quinones, a novel type of geroprotectors". Aging. 1 (5): 481–489. doi:10.18632/aging.100049. ISSN 1945-4589. PMC 2830047. PMID 20195487.
  12. ^ Gruber, Jan; Fong, Sheng; Chen, Ce-Belle; Yoong, Sialee; Pastorin, Giorgia; Schaffer, Sebastian; Cheah, Irwin; Halliwell, Barry (September 2013). "Mitochondria-targeted antioxidants and metabolic modulators as pharmacological interventions to slow ageing". Biotechnology Advances. 31 (5): 563–592. doi:10.1016/j.biotechadv.2012.09.005. ISSN 1873-1899. PMID 23022622.
  13. ^ Anisimov, V. N.; Egorov, M. V.; Krasilshchikova, M. S.; Lyamzaev, K. G.; Manskikh, V. N.; Moshkin, M. P.; Novikov, E. A.; Popovich, I. G.; Rogovin, K. A.; Shabalina, I. G.; Shekarova, O. N.; Skulachev, M. V.; Titova, T. V.; Vygodin, V. A.; Vyssokikh, M. Y.; Yurova, M. N.; Zabezhinsky, M. A.; Skulachev, V. P. (2011). "Aging". www.aging-us.com. 3 (11): 1110–1119. doi:10.18632/aging.100404. PMC 3249456. PMID 22166671. Retrieved 2019-09-18.
  14. ^ Skulachev, Vladimir P.; Anisimov, Vladimir N.; Antonenko, Yuri N.; Bakeeva, Lora E.; Chernyak, Boris V.; Erichev, Valery P.; Filenko, Oleg F.; Kalinina, Natalya I.; Kapelko, Valery I. (2009-05-01). "An attempt to prevent senescence: A mitochondrial approach". Biochimica et Biophysica Acta (BBA) - Bioenergetics. Mitochondrial Physiology and Pathology. 1787 (5): 437–461. doi:10.1016/j.bbabio.2008.12.008. ISSN 0005-2728. PMID 19159610.
  15. ^ Skulachev, M. V.; Antonenko, Y. N.; Anisimov, V. N.; Chernyak, B. V.; Cherepanov, D. A.; Chistyakov, V. A.; Egorov, M. V.; Kolosova, N. G.; Korshunova, G. A. (June 2011). "Mitochondrial-targeted plastoquinone derivatives. Effect on senescence and acute age-related pathologies". Current Drug Targets. 12 (6): 800–826. doi:10.2174/138945011795528859. ISSN 1873-5592. PMID 21269268.
  16. ^ Фырнин, Дмитрий. "Проект SkQ — ионы Скулачева: теория, продукты, команда". skq.one (in Russian). Retrieved 2019-09-18.
  17. ^ "Визомитин® (Vizomitin) - инструкция по применению, состав, аналоги препарата, дозировки, побочные действия". www.rlsnet.ru. Retrieved 2019-09-18.
  18. ^ "Home | Mitotech SA". www.mitotechpharma.com. Retrieved 2019-09-18.
  19. ^ Skulachev, V. P. (July 2012). "What is "phenoptosis" and how to fight it?". Biochemistry. Biokhimiia. 77 (7): 689–706. doi:10.1134/S0006297912070012. ISSN 1608-3040. PMID 22817532. S2CID 18053627.
  20. ^ "Реестр Клинических исследований - ClinLine". clinline.ru. Retrieved 2019-09-18.
  21. ^ Адрес: 119234, Учредитель: Некоммерческое партнерство «Международное партнерство распространения научных знаний»; Москва, г; ГСП-1; горы, Ленинские; МГУ; Д. 1; Стр. 46; адрес: 119234, офис 138 Почтовый; Москва, г (2017-07-17). "Антиоксидант SkQ1 оказался сильным антибиотиком". «Научная Россия» — наука в деталях! (in Russian). Retrieved 2019-09-18.{{cite web}}: CS1 maint: numeric names: authors list (link)
  22. ^ Nazarov, Pavel A.; Osterman, Ilya A.; Tokarchuk, Artem V.; Karakozova, Marina V.; Korshunova, Galina A.; Lyamzaev, Konstantin G.; Skulachev, Maxim V.; Kotova, Elena A.; Skulachev, Vladimir P. (2017-05-03). "Mitochondria-targeted antioxidants as highly effective antibiotics". Scientific Reports. 7 (1): 1394. Bibcode:2017NatSR...7.1394N. doi:10.1038/s41598-017-00802-8. ISSN 2045-2322. PMC 5431119. PMID 28469140.
  23. ^ "Проект "Ионы Скулачева" SKQ: PIPELINE". skq.one. Retrieved 2019-09-18.
  24. ^ Antonenko, Y. N.; Avetisyan, A. V.; Bakeeva, L. E.; Chernyak, B. V.; Chertkov, V. A.; Domnina, L. V.; Ivanova, O. Yu.; Izyumov, D. S.; Khailova, L. S. (December 2008). "Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 1. Cationic plastoquinone derivatives: Synthesis and in vitro studies". Biochemistry (Moscow). 73 (12): 1273–1287. doi:10.1134/S0006297908120018. ISSN 0006-2979. PMID 19120014. S2CID 24963667.
  25. ^ Anisimov, Vladimir N.; Egorov, Maxim V.; Krasilshchikova, Marina S.; Lyamzaev, Konstantin G.; Manskikh, Vasily N.; Moshkin, Mikhail P.; Novikov, Evgeny A.; Popovich, Irina G.; Rogovin, Konstantin A. (November 2011). "Effects of the mitochondria-targeted antioxidant SkQ1 on lifespan of rodents". Aging. 3 (11): 1110–1119. doi:10.18632/aging.100404. ISSN 1945-4589. PMC 3249456. PMID 22166671.
  26. ^ Lyamzaev, Konstantin G.; Pustovidko, Antonina V.; Simonyan, Ruben A.; Rokitskaya, Tatyana I.; Domnina, Lidia V.; Ivanova, Olga Yu.; Severina, Inna I.; Sumbatyan, Natalia V.; Korshunova, Galina A. (November 2011). "Novel Mitochondria-Targeted Antioxidants: Plastoquinone Conjugated with Cationic Plant Alkaloids Berberine and Palmatine". Pharmaceutical Research. 28 (11): 2883–2895. doi:10.1007/s11095-011-0504-8. ISSN 0724-8741. PMID 21671134. S2CID 19431821.
  27. ^ Anisimov, Vladimir N.; Egorov, Maxim V.; Krasilshchikova, Marina S.; Lyamzaev, Konstantin G.; Manskikh, Vasily N.; Moshkin, Mikhail P.; Novikov, Evgeny A.; Popovich, Irina G.; Rogovin, Konstantin A. (November 2011). "Effects of the mitochondria-targeted antioxidant SkQ1 on lifespan of rodents". Aging. 3 (11): 1110–1119. doi:10.18632/aging.100404. ISSN 1945-4589. PMC 3249456. PMID 22166671.
  28. ^ Skulachev, Vladimir P.; Antonenko, Yury N.; Cherepanov, Dmitry A.; Chernyak, Boris V.; Izyumov, Denis S.; Khailova, Ludmila S.; Klishin, Sergey S.; Korshunova, Galina A.; Lyamzaev, Konstantin G. (June 2010). "Prevention of cardiolipin oxidation and fatty acid cycling as two antioxidant mechanisms of cationic derivatives of plastoquinone (SkQs)". Biochimica et Biophysica Acta (BBA) - Bioenergetics. 1797 (6–7): 878–889. doi:10.1016/j.bbabio.2010.03.015. PMID 20307489.
  29. ^ Skulachev, Vladimir P. (November 2013). "Cationic antioxidants as a powerful tool against mitochondrial oxidative stress". Biochemical and Biophysical Research Communications. 441 (2): 275–279. doi:10.1016/j.bbrc.2013.10.063. PMID 24161394.
  30. ^ Antonenko, Y. N.; Avetisyan, A. V.; Bakeeva, L. E.; Chernyak, B. V.; Chertkov, V. A.; Domnina, L. V.; Ivanova, O. Yu.; Izyumov, D. S.; Khailova, L. S. (December 2008). "Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 1. Cationic plastoquinone derivatives: Synthesis and in vitro studies". Biochemistry (Moscow). 73 (12): 1273–1287. doi:10.1134/S0006297908120018. ISSN 0006-2979. PMID 19120014. S2CID 24963667.
  31. ^ Skulachev, Vladimir P.; Antonenko, Yury N.; Cherepanov, Dmitry A.; Chernyak, Boris V.; Izyumov, Denis S.; Khailova, Ludmila S.; Klishin, Sergey S.; Korshunova, Galina A.; Lyamzaev, Konstantin G. (June 2010). "Prevention of cardiolipin oxidation and fatty acid cycling as two antioxidant mechanisms of cationic derivatives of plastoquinone (SkQs)". Biochimica et Biophysica Acta (BBA) - Bioenergetics. 1797 (6–7): 878–889. doi:10.1016/j.bbabio.2010.03.015. PMID 20307489.
  32. ^ Skulachev, Vladimir P.; Antonenko, Yury N.; Cherepanov, Dmitry A.; Chernyak, Boris V.; Izyumov, Denis S.; Khailova, Ludmila S.; Klishin, Sergey S.; Korshunova, Galina A.; Lyamzaev, Konstantin G. (June 2010). "Prevention of cardiolipin oxidation and fatty acid cycling as two antioxidant mechanisms of cationic derivatives of plastoquinone (SkQs)". Biochimica et Biophysica Acta (BBA) - Bioenergetics. 1797 (6–7): 878–889. doi:10.1016/j.bbabio.2010.03.015. PMID 20307489.
  33. ^ Severin, F. F.; Severina, I. I.; Antonenko, Y. N.; Rokitskaya, T. I.; Cherepanov, D. A.; Mokhova, E. N.; Vyssokikh, M. Y.; Pustovidko, A. V.; Markova, O. V. (2010-01-12). "Penetrating cation/fatty acid anion pair as a mitochondria-targeted protonophore". Proceedings of the National Academy of Sciences. 107 (2): 663–668. Bibcode:2010PNAS..107..663S. doi:10.1073/pnas.0910216107. ISSN 0027-8424. PMC 2818959. PMID 20080732.
  34. ^ Korshunov, S. S.; Skulachev, V. P.; Starkov, A. A. (1997-10-13). "High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria". FEBS Letters. 416 (1): 15–18. Bibcode:1997FEBSL.416...15K. doi:10.1016/s0014-5793(97)01159-9. ISSN 0014-5793. PMID 9369223.
  35. ^ Antonenko, Y. N.; Avetisyan, A. V.; Bakeeva, L. E.; Chernyak, B. V.; Chertkov, V. A.; Domnina, L. V.; Ivanova, O. Yu.; Izyumov, D. S.; Khailova, L. S. (December 2008). "Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 1. Cationic plastoquinone derivatives: Synthesis and in vitro studies". Biochemistry (Moscow). 73 (12): 1273–1287. doi:10.1134/S0006297908120018. ISSN 0006-2979. PMID 19120014. S2CID 24963667.
  36. ^ Фырнин, Дмитрий. "Проект SkQ — ионы Скулачева: теория, продукты, команда". skq.one (in Russian). Retrieved 2019-09-20.
  37. ^ Knorre, Dmitry A.; Markova, Olga V.; Smirnova, Ekaterina A.; Karavaeva, Iuliia E.; Sokolov, Svyatoslav S.; Severin, Fedor F. (August 2014). "Dodecyltriphenylphosphonium inhibits multiple drug resistance in the yeast Saccharomyces cerevisiae". Biochemical and Biophysical Research Communications. 450 (4): 1481–1484. doi:10.1016/j.bbrc.2014.07.017. PMID 25019981.
  38. ^ Anisimov, Vladimir N.; Egorov, Maxim V.; Krasilshchikova, Marina S.; Lyamzaev, Konstantin G.; Manskikh, Vasily N.; Moshkin, Mikhail P.; Novikov, Evgeny A.; Popovich, Irina G.; Rogovin, Konstantin A. (November 2011). "Effects of the mitochondria-targeted antioxidant SkQ1 on lifespan of rodents". Aging. 3 (11): 1110–1119. doi:10.18632/aging.100404. ISSN 1945-4589. PMC 3249456. PMID 22166671.
  39. ^ Skulachev, M. V.; Antonenko, Y. N.; Anisimov, V. N.; Chernyak, B. V.; Cherepanov, D. A.; Chistyakov, V. A.; Egorov, M. V.; Kolosova, N. G.; Korshunova, G. A. (2011-05-31). "Mitochondrial-Targeted Plastoquinone Derivatives. Effect on Senescence and Acute Age-Related Pathologies". Current Drug Targets. 12 (6): 800–26. doi:10.2174/138945011795528859. PMID 21269268. Retrieved 2019-09-20.
  40. ^ Shabalina, I. G.; Vyssokikh, M. Y.; Gibanova, N.; Csikasz, R. I.; Edgar, D.; Hallden-Waldemarson, A.; Rozhdestvenskaya, Z.; Bakeeva, L. E.; Vays, V. B.; Pustovidko, A. V.; Skulachev, M. V.; Cannon, B.; Skulachev, V. P.; Nedergaard, J. (2017). "Aging". www.aging-us.com. 9 (2): 315–339. doi:10.18632/aging.101174. PMC 5361666. PMID 28209927. Retrieved 2019-09-20.
  41. ^ Demianenko, I. A.; Vasilieva, T. V.; Domnina, L. V.; Dugina, V. B.; Egorov, M. V.; Ivanova, O. Y.; Ilinskaya, O. P.; Pletjushkina, O. Y.; Popova, E. N. (March 2010). "Novel mitochondria-targeted antioxidants, "Skulachev-ion" derivatives, accelerate dermal wound healing in animals". Biochemistry. Biokhimiia. 75 (3): 274–280. doi:10.1134/s000629791003003x. ISSN 1608-3040. PMID 20370605. S2CID 36725345.
  42. ^ Skulachev, Vladimir P.; Anisimov, Vladimir N.; Antonenko, Yuri N.; Bakeeva, Lora E.; Chernyak, Boris V.; Erichev, Valery P.; Filenko, Oleg F.; Kalinina, Natalya I.; Kapelko, Valery I. (May 2009). "An attempt to prevent senescence: A mitochondrial approach". Biochimica et Biophysica Acta (BBA) - Bioenergetics. 1787 (5): 437–461. doi:10.1016/j.bbabio.2008.12.008. PMID 19159610.
  43. ^ Brzheskiy, Vladimir V.; Efimova, Elena L.; Vorontsova, Tatiana N.; Alekseev, Vladimir N.; Gusarevich, Olga G.; Shaidurova, Ksenia N.; Ryabtseva, Alla A.; Andryukhina, Olga M.; Kamenskikh, Tatiana G. (December 2015). "Results of a Multicenter, Randomized, Double-Masked, Placebo-Controlled Clinical Study of the Efficacy and Safety of Visomitin Eye Drops in Patients with Dry Eye Syndrome". Advances in Therapy. 32 (12): 1263–1279. doi:10.1007/s12325-015-0273-6. ISSN 0741-238X. PMC 4679790. PMID 26660938.
  44. ^ Petrov, Anton; Perekhvatova, Natalia; Skulachev, Maxim; Stein, Linda; Ousler, George (January 2016). "SkQ1 Ophthalmic Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model". Advances in Therapy. 33 (1): 96–115. doi:10.1007/s12325-015-0274-5. ISSN 0741-238X. PMC 4735228. PMID 26733410.
  45. ^ "Реестр Клинических исследований - ClinLine". clinline.ru. Retrieved 2019-09-20.
  46. ^ Janssen, Roger (2011-01-01). "Chapter II: Independent in name only". In Search of a Path. Brill. pp. 25–68. doi:10.1163/9789004253674_003. ISBN 9789004253674.
  47. ^ "Study of SkQ1 as Treatment for Dry-eye Syndrome - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2019-09-20.
  48. ^ "Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome (VISTA-2)- Full Text View - ClinicalTrials.gov". clinicaltrials.gov. 20 December 2021. Retrieved 2023-02-07.
  49. ^ "MitoVitan® / МитоВитан®: Главная". mitovitan.ru. Retrieved 2019-09-20.
  50. ^ "ЭКЗОМИТИН®". exomitin.ru. Retrieved 2019-09-20.
  51. ^ "Article". protein.bio.msu.ru. Retrieved 2019-09-20.
  52. ^ Усков, Александр Иринархович (2013). Биотехнологические основы повышения эффективности воспроизводства исходного материала в оригинальном семеноводстве картофеля (Thesis) (in Russian). Москва.
[edit]
Retrieved from "http://en.wiki.x.io/w/index.php?title=SkQ&oldid=1260701415"